Silberstein, Stephen D.
Stauffer, Virginia L.
Day, Katie A.
Lipsius, Sarah
Wilson, Maria-Carmen
Funding for this research was provided by:
Eli Lilly and Company (n/a)
Article History
Received: 18 March 2019
Accepted: 11 June 2019
First Online: 28 June 2019
Change Date: 27 December 2019
Change Type: Correction
Change Details: After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision.
Ethics approval and consent to participate
: The study protocols were reviewed and approved by the appropriate institutional review board for each of the study sites. All patients gave written informed consent to participate in the study. The studies were conducted with the approval of the independent Ethics Committees of the participating institutes and in accordance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice guidelines, and local regulations.
: Not applicable.
: VLS and KD are full-time employees of Eli Lilly and Company and own stock in the company. SL is a full-time employee of Syneos Health. M-CW is a consultant and/or advisory panel member and have received honoraria from Allergan, Inc.; Amgen; electroCore Medical, LLC; Lilly USA, LLC; Teva Pharmaceuticals. SS is a consultant and/or advisory panel member and has received honoraria from Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Cefaly; Curelator, Inc.; Dr. Reddy’s Laboratories; Egalet Corporation; eNeura Inc.; electroCore Medical, LLC; Lilly USA, LLC; Medscape, LLC.; NINDS; Satsuma Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; and Trigemina, Inc.